Skip to main
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 42%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is a digital healthcare company that has a positive outlook, supported by their expanding business of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow quicker and more efficient diagnosis. Q1 2026 results showed revenue growth of 26% y/y with plans to launch Zio MCT and Gen 3 algorithm in 1H27 and potential savings of over $100M. Although there are risks such as delays to product launches and potential impacts from regulatory actions, we believe the company's durable revenue growth profile and potential for profitability make it a Buy with a $185 price target based on a ~6x projected 12-24 month revenue estimate.

Bears say

iRhythm Holdings is heavily reliant on a successful launch of their Zio MCT product, which has been delayed several times. With only 53% of accounts being EHR integrated, there is limited potential for widespread adoption in the near term, making it difficult for revenues to catch up with their high operating expenses. Additionally, despite their 2026 Guidance anticipating only 17-18% revenue growth and low double digit EBITDA margins, the company's current valuation is not justified, as it is trading at a much higher multiple compared to its peers in the digital healthcare industry.

iRhythm Technologies (IRTC) has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 42% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 12 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $180.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $180.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.